A short-term evaluation of semen and accessory sex gland function in phase III trial subjects receiving intravasal contraceptive RISUG

• Published in: Contraception (Stoneham) Vol. 67; no. 1; pp. 73 - 78
• Main Authors: Chaki, S.P., Das, H.C., Misro, M.M.
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 2003; Elsevier Science
• Subjects: Acid Phosphatase - analysis; Adult; Biological and medical sciences; Birth control; Contraceptive Agents, Male - pharmacology; Dimethyl Sulfoxide - pharmacology; Female; Fructose - analysis; Genitalia, Male - drug effects; Gynecology. Andrology. Obstetrics; Humans; Male; Maleates - pharmacology; Medical sciences; New male contraceptive; Other methods of contraception. Sterilization; Polyesters; Polystyrenes; Pregnancy; Pregnancy Rate; RISUG; Semen - chemistry; Semen - cytology; Semen - drug effects; Semen analysis; Semen biochemistry; Sperm and germ cell morphology; Sperm Count; Spermatozoa - drug effects; Styrenes - pharmacology; RISUG; Sperm and germ cell morphology; Semen analysis; Semen biochemistry; New male contraceptive; Phase III trial; Human; Biological fluid; Spermatozoa; Semen; Male; Contraception; Germinal cell; Male genital system; Vas deferens; Epididymis; Morphology; Maleic anhydride copolymer; Styrene copolymer

Following the intravasal injection of a new male contraceptive RISUG (reversible inhibition of sperm under guidance) in volunteers, routine semen analysis, semen biochemistry and germ cell morphology were evaluated in comparison with the corresponding preinjection samples for a maximum period of 6 m...